Coagulation Cascade Pathology

The Three-Pathway Model and Tissue Factor Initiation

• Extrinsic pathway initiation: Tissue injury exposes Tissue Factor (TF/Factor III) in the subendothelium; TF binds Factor VII (the only vitamin K-dependent factor in extrinsic pathway) forming the TF-Factor VIIa complex, which directly activates Factor X to Factor Xa
• Intrinsic pathway amplification: Contact activation (exposure to negatively charged surfaces) triggers Factor XII → Factor XIIa, which sequentially activates Factor XI → Factor XIa, which activates Factor IX → Factor IXa; Factor IXa complexes with its cofactor Factor VIIIa (produced by endothelium and megakaryocytes) to form the "tenase complex" that converts Factor X → Factor Xa
• Common pathway convergence: Both pathways funnel through Factor X activation; Factor Xa combines with Factor V (platelet cofactor, synthesized in liver and megakaryocytes) to form the "prothrombinase complex," which catalyzes the critical conversion of Factor II (prothrombin) → Factor IIa (thrombin)

Thrombin as the Central Hub and Fibrin Formation

• Thrombin (Factor IIa) is the most potent serine protease in the cascade and serves as the ultimate amplification center: it cleaves fibrinogen → fibrin monomers, which polymerize into loose clots
• Thrombin activates Factor XIII (fibrin-stabilizing factor/transglutaminase) which cross-links fibrin polymers through covalent γ-glutamyl-lysine bonds, creating mechanically stable, plasmin-resistant clots
• Thrombin paradoxically activates natural anticoagulants: it binds thrombomodulin (endothelial surface protein) to activate Protein C, which inactivates Factors Va and VIIIa (negative feedback); this is the critical anticoagulant switch that prevents cascade runaway

Vitamin K-Dependent Factors and Calcium Cofactor Requirements

• Factors II, VII, IX, and X require γ-carboxylation of glutamic acid residues (mediated by Vitamin K) to achieve calcium-dependent binding to phospholipid membranes; this carboxylation is essential for their enzymatic activity
• All cascade reactions occur on phospholipid surfaces (platelet membranes, tissue factor membranes, or administered anticoagulant-bound surfaces); reactions in plasma alone are dramatically slower, explaining why platelet plug formation is prerequisite to cascade activation
• Calcium (citrate-sensitive cofactor) bridges enzyme, substrate, and phospholipid surfaces; EDTA anticoagulant chelates calcium and halts cascade, used in coagulation studies

Natural Anticoagulant Mechanisms and Pathologic Imbalance

• Protein C pathway: Thrombomodulin-bound thrombin activates Protein C (Vitamin K-dependent); Protein S (Vitamin K-dependent cofactor, produced in liver/endothelium) acts as a bridging cofactor allowing Protein C to inactivate Factors Va and VIIIa
• Tissue Factor Pathway Inhibitor (TFPI): A lipoprotein-associated protease inhibitor that directly blocks the TF-Factor VIIa complex and Factor Xa, providing critical braking of extrinsic pathway initiation
• Antithrombin III (ATIII): A serine protease inhibitor (serpin) that irreversibly inactivates thrombin, Factors IXa, Xa, XIa, and XIIa; binding is dramatically accelerated by heparin and heparan sulfate (endothelial surface), making anticoagulants clinically effective
• Fibrinolytic cascade: Plasmin (generated from plasminogen by tissue plasminogen activator [tPA] or urokinase plasminogen activator [uPA]) degrades fibrin clots into D-dimers; plasminogen activator inhibitor (PAI-1) and α2-antiplasmin limit fibrinolysis

Inherited Thrombophilias (Hypercoagulable States)

• Factor V Leiden (Factor V R506Q mutation): Most common inherited thrombophilia (5% of Caucasians, heterozygous 3-7× VTE risk, homozygous 80× risk); mutation prevents Protein C cleavage of Factor Va, perpetuating Factor Va activity
• Prothrombin G20210A mutation: Second most common inherited thrombophilia (2% Caucasians, 2-3× VTE risk); increases prothrombin mRNA stability and plasma Factor II levels
• Antithrombin III deficiency: Autosomal dominant inheritance; Type I (quantitative) or Type II (qualitative); carriers have high spontaneous VTE risk (50-60% lifetime), often with recurrent thrombosis by age 20-30
• Protein C or Protein S deficiency: Autosomal dominant; Type I (quantitative) or Type II (qualitative); increased VTE risk; neonates with homozygous deficiency develop purpura fulminans (acute DIC-like consumptive coagulopathy with skin necrosis)
• Dysfibrinogenemia: Qualitative fibrinogen abnormalities; most are asymptomatic, but some variants cause bleeding or thrombosis
• Elevated Factor VIII or Factor XI: Increased plasma levels confer thrombotic risk; Factor VIII elevation is particularly associated with VTE

Acquired Thrombophilias

• Antiphospholipid syndrome: Autoimmune condition with circulating IgG/IgM against cardiolipin, β2-glycoprotein-I, or phosphatidylserine; causes lupus anticoagulant (paradoxically prolonged aPTT despite hypercoagulable state); associated with recurrent VTE, arterial thrombosis, and pregnancy morbidity
• Malignancy: Direct tissue factor expression by cancer cells; cancer-associated thrombosis is major cause of VTE in hospitalized patients
• Immobilization: Prolonged bed rest, long flights reduce venous return and cause blood stasis, predisposing to DVT
• Oral contraceptives and hormone replacement therapy: Estrogen increases production of Factors II, VII, X and fibrinogen while reducing Protein S levels
• Nephrotic syndrome: Loss of Protein C, Protein S, and Antithrombin III in urine causes acquired thrombophilia; particularly high VTE risk with membranoproliferative GN

Acquired Bleeding Disorders (Hypocoagulable States)

• Liver disease: Hepatocytes synthesize Factors II, V, VII, IX, X, XI, XII, XIII; cirrhosis causes quantitative deficiency of all vitamin K-dependent factors and Factor V; prolonged PT, aPTT, low fibrinogen
• Vitamin K deficiency: Results in undercarboxylation of Factors II, VII, IX, X, and Proteins C and S; etiologies include antibiotic use (disrupts gut flora), malabsorption, dietary insufficiency; PT prolongation precedes aPTT (Factor VII has shortest half-life)
• Disseminated intravascular coagulation (DIC): Systemic thrombin generation overwhelming natural anticoagulants; causes consumption of all factors and platelets with paradoxical bleeding; etiologies include sepsis, trauma, malignancy (especially APL), amniotic fluid embolism, placental abruption
• Heparin-induced thrombocytopenia (HIT): IgG antibodies against heparin-platelet factor 4 complex cause platelet activation and paradoxical thrombosis; represents immune-mediated prothrombotic state with thrombocytopenia
• Massive transfusion: Dilutional coagulopathy from replacement with crystalloid/packed RBCs lacking clotting factors; Factor V and fibrinogen depleted first
• Therapeutic anticoagulation: Warfarin inhibits Vitamin K recycling (blocking Factors II, VII, IX, X); heparin directly activates Antithrombin III; direct Factor Xa and IIa inhibitors create iatrogenic deficiency states

Intrinsic Factor Deficiencies (Inherited)

• Factor VIII deficiency (Hemophilia A): X-linked recessive; most common severe inherited bleeding disorder; Factor VIII is cofactor for tenase complex; accounts for 80% of hemophilia
• Factor IX deficiency (Hemophilia B/Christmas disease): X-linked recessive; less common than Factor VIII but clinically indistinguishable
• Factor V deficiency: Autosomal recessive; rare; combined deficiency of Factor V and Factor VIII occurs in type II combined factor deficiency (LMAN1 mutation affecting vesicular transport)
• Factor X deficiency: Autosomal recessive; rare; severe deficiency presents with severe bleeding
• Factor II deficiency: Rare; vitamin K-dependent; causes severe bleeding
• Factor XI deficiency: Autosomal recessive; high frequency in Ashkenazi Jewish population (8%); paradoxically mild bleeding despite prolonged aPTT; bleeding risk increases with triggers (surgery, trauma)
• Factor XII deficiency: Isolated aPTT prolongation without bleeding risk; contact factor for intrinsic pathway; clinically silent finding on routine coagulation screening
• von Willebrand disease: Most common inherited bleeding disorder (1-3% prevalence); von Willebrand factor carries Factor VIII and mediates platelet adhesion; three types based on quantitative/qualitative deficiency; Type I most common

Hypercoagulable States (Thrombophilia)

• Deep vein thrombosis (DVT): Unilateral leg swelling, erythema, warmth, pain with dorsiflexion (Homan's sign, insensitive); palpable cord representing thrombosed vein; pain worse with standing or walking; can progress to compartment syndrome or phlegmasia cerulea dolens (massive iliofemoral thrombosis with limb-threatening venous gangrene)
• Pulmonary embolism: Acute dyspnea, pleuritic chest pain, syncope (massive PE), hemoptysis (infarction); tachycardia, tachypnea, hypoxemia; mortality 10-30% if untreated
• Upper extremity thrombosis: Less common; associated with indwelling catheters or thoracic outlet syndrome
• Visceral/portal vein thrombosis: Abdominal pain; risk of bowel infarction and hemorrhage
• Arterial thrombosis: Stroke, myocardial infarction, limb ischemia; particularly in antiphospholipid syndrome or malignancy

• Recurrent spontaneous thrombosis: Multiple thrombotic events in young patients (<50 years) suggests inherited thrombophilia; recurrent provoked thrombosis suggests acquired disorder
• Postthrombotic syndrome: Chronic venous insufficiency (20-50% post-DVT); manifests as leg edema, skin pigmentation changes, lipodermatosclerosis, venous claudication from valve destruction by thrombus
• Chronic thromboembolic pulmonary hypertension: Develops in 2-4% post-PE; progressive dyspnea and right heart failure from recurrent PE or incomplete resolution

• Obstetric complications: Recurrent first and second-trimester miscarriages, intrauterine growth restriction, preeclampsia from placental infarction and vasculopathy
• Livedo reticularis: Lacy vascular pattern from dermal microvasculature thrombosis
• Thrombocytopenia: Often mild (50,000-100,000/μL); represents consumption rather than decreased production

Hypocoagulable States (Bleeding Disorders)

• Spontaneous bleeding: Indicates severe deficiency (typically Factor levels <1%); presents as spontaneous hematomas (muscle, retroperitoneum), hemarthroses (joint bleeds causing permanent arthropathy), intracranial hemorrhage (highest mortality), GI bleeding
• Post-traumatic/post-surgical bleeding: More common than spontaneous in moderate deficiencies; delayed bleeding (hours to days post-injury) suggests cascade deficiency (vs. platelet/vWF disorder which bleeds immediately)
• Mucosal bleeding: Epistaxis, gingival bleeding, menorrhagia (especially in vWF deficiency); less typical for isolated factor deficiencies
• Hematuria: May indicate renal infarction from VTE in cancer patients on anticoagulation

• Acute DIC: Septic patient develops sudden widespread bleeding (orificial, puncture sites, surgical wounds), acral necrosis (fingertips, toes—purpura fulminans), microangiopathic hemolytic anemia (schistocytes on blood smear)
• Chronic DIC: Compensated state in cancer patients; subclinical consumption with slowly declining platelets and fibrinogen; risk of sudden decompensation

• Acute presentation: Sudden onset of bleeding (spontaneous GI hemorrhage, intracranial hemorrhage) in patients on antibiotics or with malabsorption
• Subtle manifestations: Spontaneous bruising, gingival bleeding; PT prolongation often first coagulation abnormality (Factor VII has shortest 6-hour half-life)

• Hemophilia A/B manifestations by severity:
• Severe (Factor <1%): Spontaneous hemarthroses (typically knee, elbow, ankle—weight-bearing joints), spontaneous intracranial bleeding, retroperitoneal bleeding; recurrent bleeding into same joint causes hemophilic arthropathy with chronic synovitis, cartilage destruction, joint fibrosis, limited range of motion
• Moderate (1-5%): Bleeding with minor trauma, post-surgical bleeding; rarely spontaneous
• Mild (<5-40%): Only symptomatic with major trauma or surgery; often undiagnosed until hemostatic challenge

• Factor XI deficiency: Paradoxically mild clinical bleeding despite prolonged aPTT; bleeding typically requires hemostatic challenge (surgery, trauma); explains historical association with "benign aPTT prolongation"

• von Willebrand disease: Mucocutaneous bleeding pattern (epistaxis, gingival bleeding, menorrhagia); bruising; aPTT may be prolonged (secondary to reduced Factor VIII); prolonged bleeding time or PFA-100 prolongation; Type I (70% of cases) shows partial quantitative deficiency; Type II shows **qualitative abnormality or disproportion between vWF:Ag and

Initial screening panel

• PT/INR: interrogates the extrinsic and common pathways (VII, X, V, II, fibrinogen); isolated prolongation points to factor VII deficiency, early vitamin K deficiency, or warfarin, because factor VII has the shortest half-life
• aPTT: interrogates the intrinsic and common pathways (XII, XI, IX, VIII plus common factors); isolated prolongation suggests hemophilia A/B, factor XI or XII deficiency, von Willebrand disease (via low FVIII), unfractionated heparin, or a lupus anticoagulant
• Both prolonged: common-pathway defect, severe liver disease, DIC, direct thrombin inhibitors, or profound vitamin K deficiency; check fibrinogen and thrombin time to isolate the terminal step
• Platelet count and peripheral smear: mandatory before attributing bleeding to the cascade; schistocytes indicate microangiopathy/DIC

Confirmatory testing

• 1:1 mixing study: the single best next step for any unexplained prolonged aPTT — correction implies factor deficiency; failure to correct implies an inhibitor (acquired factor VIII autoantibody or lupus anticoagulant). Incubate at 37°C for time- and temperature-dependent FVIII inhibitors; quantify by Bethesda assay
• Specific factor activity assays: gold standard for hemophilia; severity is graded by residual activity (<1% severe, 1–5% moderate, >5–40% mild)
• von Willebrand panel: vWF:Ag, vWF platelet-binding activity (ristocetin cofactor), FVIII activity, and multimer analysis, per the 2021 ASH/ISTH/NHF/WFH von Willebrand disease guidelines
• Vitamin K deficiency versus liver disease: factor V is normal in vitamin K deficiency and low in hepatic synthetic failure; PT corrects after parenteral vitamin K only in the former

Named criteria and scores

• ISTH overt DIC score: platelet count, elevated fibrin-related marker (D-dimer), PT prolongation, and fibrinogen; a score at or above the ISTH threshold is compatible with overt DIC and requires serial re-scoring
• 4Ts score stratifies HIT probability; confirm with anti-PF4/heparin immunoassay and, when needed, the functional serotonin release assay
• Revised Sapporo (Sydney) criteria for antiphospholipid syndrome require a clinical event plus a persistently positive antibody on testing repeated at least 12 weeks apart
• Thrombophilia testing is unreliable during acute thrombosis or on anticoagulation; APC-resistance screening confirmed by factor V Leiden genotyping, prothrombin G20210A PCR, and functional antithrombin/protein C/protein S assays

Immediate stabilization of the bleeding patient

• Hold the offending anticoagulant, apply local hemostasis, transfuse for hemodynamic instability; send fibrinogen and factor levels before replacement when feasible
• Warfarin-associated major bleeding: vitamin K IV plus 4-factor prothrombin complex concentrate; the ACC expert consensus on oral anticoagulant reversal and ASH favor PCC over FFP because of faster INR correction and lower volume load
• DOAC reversal: idarucizumab (monoclonal antibody fragment) for dabigatran; andexanet alfa (decoy factor Xa) for apixaban/rivaroxaban
• Heparin: protamine sulfate fully reverses unfractionated heparin and only partially reverses LMWH

Factor deficiency states

• Factor concentrates: recombinant FVIII for hemophilia A, recombinant FIX for hemophilia B, dosed to a target activity level by bleed site — WFH guidelines endorse prophylaxis over on-demand therapy for severe disease
• Emicizumab: bispecific antibody bridging FIXa and FX (mimics FVIIIa) for subcutaneous prophylaxis, effective even with inhibitors
• Desmopressin: releases endothelial vWF/FVIII stores; useful in mild hemophilia A and type 1 vWD, useless in hemophilia B and type 3 vWD; watch for hyponatremia
• Antifibrinolytics: tranexamic acid or aminocaproic acid for mucosal and dental bleeding
• Inhibitor-positive patients: bypassing agents (recombinant factor VIIa, activated PCC) plus immune tolerance induction

Disease-specific management

• DIC: treat the precipitant; per ISTH guidance transfuse platelets, plasma, and cryoprecipitate for critically low fibrinogen only if bleeding or before procedures — do not transfuse to correct numbers alone
• VTE: ASH 2020 VTE guidelines favor DOACs over vitamin K antagonists for most acute VTE, minimum three months
• HIT: stop all heparin and start a non-heparin anticoagulant (argatroban, bivalirudin, or fondaparinux)

Contraindicated

• Warfarin in acute HIT or protein C deficiency before platelet recovery/adequate parallel anticoagulation — precipitates venous limb gangrene and warfarin skin necrosis
• DOACs in triple-positive antiphospholipid syndrome; use a vitamin K antagonist
• All ACE inhibitors and warfarin in pregnancy; heparins do not cross the placenta
• Aspirin, NSAIDs, and intramuscular injections in hemophilia

Complications of the bleeding disorders

• Intracranial hemorrhage: leading cause of hemophilia-related death; any headache, vomiting, or altered mental status in a factor-deficient patient is a true emergency — give factor replacement before imaging
• Hemophilic arthropathy: repeated intra-articular blood deposits iron in synovium, driving synovitis, cartilage destruction, and fixed joint contracture; signaled by a warm, tense joint held in flexion
• Iliopsoas and retroperitoneal hematoma: presents with flank/groin pain, hip flexion posture, and a femoral neuropathy (paresthesia over the anterior thigh); large-volume blood loss can be occult
• Compartment syndrome: intramuscular bleed raising compartment pressure; pain out of proportion and pain on passive stretch — a surgical emergency
• Purpura fulminans: homozygous protein C or S deficiency in neonates, or acute meningococcemia; dermal microvascular thrombosis with retiform necrosis

Complications of the thrombotic disorders

• DIC-related multiorgan failure: microthrombi produce acute kidney injury, ARDS, and acral gangrene while consumption causes simultaneous bleeding — the defining paradox
• Catastrophic antiphospholipid syndrome: rapid multi-territory small-vessel thrombosis with organ failure; emergency requiring anticoagulation, corticosteroids, and plasma exchange

Complications of treatment

• Neutralizing inhibitors (alloantibodies): develop in a substantial minority of severe hemophilia A patients exposed to factor VIII; signaled by bleeding that no longer responds to adequate factor dosing and a non-correcting mixing study
• Anaphylaxis and nephrotic syndrome: characteristically follow FIX exposure and immune tolerance induction in inhibitor-positive hemophilia B
• Heparin-induced thrombocytopenia: anti-PF4 IgG activates platelets, so the thrombocytopenia is prothrombotic; flagged by a platelet drop typically 5–10 days into heparin exposure
• Warfarin-induced skin necrosis: protein C (short half-life) falls before factors II and X, creating transient hypercoagulability; necrotic plaques over fat-rich areas within the first days of therapy
• Heparin-related osteoporosis and hyperkalemia (aldosterone suppression) with prolonged unfractionated heparin
• Tranexamic acid: avoid in upper-tract hematuria — clot retention can obstruct the ureter
• Andexanet alfa: associated with thrombotic events after reversal

• PT tracks the extrinsic pathway, aPTT the intrinsic: mnemonic — PeT (Play Table Tennis, extrinsic/PT) versus PiTT (intrinsic/PTT). Warfarin and early vitamin K deficiency prolong PT first because factor VII has the shortest half-life
• Prolonged aPTT with a normal PT and normal platelets in a boy with hemarthrosis = hemophilia A or B; the single best next step is a 1:1 mixing study, then specific factor activity assays
• Mixing study logic is the examiners' favorite: corrects = deficiency (replace the factor); does not correct = inhibitor (acquired FVIII autoantibody or lupus anticoagulant)
• Factor XII deficiency: strikingly prolonged aPTT with no bleeding whatsoever — the classic distractor. Factor XI deficiency (Ashkenazi Jewish) causes mild, trauma-provoked bleeding disproportionate to the aPTT
• Lupus anticoagulant is a misnomer: an in vitro phospholipid-dependent aPTT prolongation that causes thrombosis in vivo; confirm persistence at 12 weeks per the revised Sapporo criteria, and use a vitamin K antagonist rather than a DOAC in triple-positive antiphospholipid syndrome
• Vitamin K deficiency versus liver failure: both prolong PT, but factor V is normal only in vitamin K deficiency (it is not vitamin K–dependent). Factor VIII is also preserved or elevated in liver disease because it is made by endothelium
• DIC gives the full picture: prolonged PT and aPTT, low platelets, low fibrinogen, high D-dimer, schistocytes — use the ISTH overt DIC score and treat the underlying trigger
• Warfarin skin necrosis in a newly anticoagulated patient points to underlying protein C deficiency; bridge with heparin. Conversely, factor V Leiden is APC resistance — screen functionally, confirm by genotype
• Mucocutaneous bleeding with a mildly prolonged aPTT = von Willebrand disease (the most common inherited bleeding disorder); think ristocetin cofactor activity and desmopressin for type 1